July 10, 2025

1 in 4 US Infants Missing Bifidobacterium: Study

Babies who lacked this key gut bacteria were at an increased risk of eczema, allergies, and asthma by age 2.

Conexiant

July 07, 2025

FDA Approves First Oral Hereditary Angioedema Treatment

FDA approves Ekterly (sebetralstat), the first oral on-demand treatment for hereditary angioedema, shown in trials to provide faster symptom relief and eliminate the need for injection.

Conexiant

July 01, 2025

FDA Approves Low-IgA IG Therapy

GAMMAGARD LIQUID ERC is the first ready-to-use liquid immunoglobulin therapy with IgA ≤2 µg/mL for primary immunodeficiency in individuals aged 2 years and older.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 24, 2025

Dermatologists Show Lowest Turnover Intent of All Specialists

AMA data show only 19.9% of dermatologists plan to leave their current positions, compared with 40.6% of anesthesiologists.

Conexiant

November 01, 2024

Are Antibiotics Needed for Pediatric Pneumonia?

Nearly one in five children diagnosed with pneumonia in outpatient settings did not receive antibiotics, according to a recent study in JAMA Network Open.

Conexiant

January 06, 2025

Does JIA Increase Arthritis Risk?

Explore how genetic overlap links juvenile idiopathic arthritis to adult rheumatic diseases.

Conexiant

November 01, 2024

Study: U.S. Faces Higher Drug Shortages

A recent study compared drug shortage risks between the U.S. and Canada, revealing that the U.S. experienced approximately a 40% higher drug shortage risk compared to Canada, with trends persisting both pre-pandemic and during COVID-19. The study highlighted that Canada's approach was associated with a lower shortage risk.

Conexiant

April 29, 2024

Nasal Neomycin May Offer Virus Protection 

A study funded by the Melinda and Bill Gates Foundation demonstrates the potential of intranasal neomycin to elicit broad-spectrum antiviral immunity in the upper respiratory tract, providing significant protection against upper respiratory infections in animal models and showing promising results in a pilot human study.

Conexiant